Ollin Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening ophthalmic conditions.
Headquartered in Austin, Texas, and established in 2023, Ollin focuses on bispecific antibodies that address multifactorial disease biology in areas such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and thyroid eye disease (TED).
The company’s lead candidate, OLN324, is a next-generation VEGF/Ang2 bispecific antibody developed in collaboration with Innovent Biologics. It has demonstrated superior anatomic outcomes and numerically greater vision gains versus faricimab (Vabysmo) in a randomized Phase 1b head-to-head study and is advancing to global Phase 3 trials in DME and wAMD in the second half of 2026.
Ollin’s pipeline also includes OLN102, a first-in-class TSHR/IGF-1R bispecific antibody for TED and Graves’ disease, developed with VelaVigo and expected to enter clinical development in 2026.
Privately held and venture-backed by investors including ARCH Venture Partners, TCGX, a16z Bio+Health, RA Capital, and others, Ollin operates as an emerging player in the ophthalmology sector, leveraging partnerships and a specialized team to challenge established treatments in the retina and ocular autoimmune markets.
Also known as Ollin Bio.
None yet. When a new project in the record names Ollin Biosciences as owner, partner or investor, it shows here.
The deal would add OLN324, a Phase 3 bispecific antibody candidate for retinal diseases, to its ophthalmology pipeline.